SCHEMBL21484749

SCHEMBL21484749

COc1ccc(-c2csc(NC(=O)CC#N)n2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.53
MAPT P10636 7/20 0.53
ALDH1A1 P00352 4/20 0.53
PKM P14618 1/20 0.53
PPP1CA P62136 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.52
RAB9A P51151 3/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 2/20 0.51
MAPK1 P28482 2/20 0.51
TP53 P04637 1/20 0.51
KMT2A Q03164 6/20 0.49
MEN1 O00255 5/20 0.49
KDM4E B2RXH2 1/20 0.49
ROCK1 Q13464 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
APP P05067 1/20 0.49
CYP3A4 P08684 2/20 0.48
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22509326 0.86 SMN1; SMN2 (0.59) MAPTALDH1A1PKMPPP1CAL3MBTL1
SCHEMBL21484832 0.85 SMN1; SMN2 (0.71) ABL1MAPTALDH1A1SMN1; SMN2RAB9A
SCHEMBL21484621 0.85 ABL1 (0.56) ABL1MAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL21516184 0.84 MAPT (0.54) MAPTALDH1A1PKMPPP1CAL3MBTL1
SCHEMBL21484693 0.83 ABL1 (0.54) ABL1MAPTALDH1A1PKMPPP1CA
SCHEMBL21484886 0.80 ABL1 (0.61) ABL1MAPTALDH1A1SMN1; SMN2RAB9A
SCHEMBL21484872 0.80 ABL1 (0.53) ABL1MAPTALDH1A1SMN1; SMN2RAB9A
SCHEMBL21484632 0.80 KMT2A (0.56) ABL1MAPTALDH1A1SMN1; SMN2RAB9A
SCHEMBL21484634 0.79 MRE11 (0.58) ABL1MAPTALDH1A1PKMPPP1CA
SCHEMBL21484682 0.78 ALDH1A1 (0.64) ABL1MAPTALDH1A1PKMPPP1CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 ABL1 4272/4885MAPT 1351/4885ALDH1A1 1635/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 ABL1 4272/4885MAPT 1351/4885ALDH1A1 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.